December 18, 2019 08:02 AM ESTUpdated 10:35 AM

After taking a hard look at the data, Novartis punts Aduro’s STING drug — the latest in a long line of setbacks

John Carroll

Editor & Founder

Things keep getting worse at the beleaguered Aduro.

Stephen Isaacs

Ten months after CEO Stephen Isaacs was forced to restructure and downsize the staff after a series of setbacks, Novartis is dumping Aduro’s lead surviving drug after concluding from the clinical data that there was no reason to push forward.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

After taking a hard look at the data, Novartis punts Aduro’s STING drug — the latest in a long line of setbacks

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Af­ter tak­ing a hard look at the da­ta, No­var­tis punts Aduro’s STING drug — the lat­est in a long line of set­backs

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

After taking a hard look at the data, Novartis punts Aduro’s STING drug — the latest in a long line of setbacks

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway